Background: 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the systemic treatment of
cancer. Treatment with FU may cause severe or life-threatening side effects and the ...treatment-related mortality rate is 0.2–1.0%. Summary: Among other risk factors associated
with increased toxicity, a genetic deficiency in dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for
the metabolism of FU, is well known. This is due to variants
in the DPD gene (DPYD). Up to 9% of European patients carry a DPD gene variant that decreases enzyme activity, and
DPD is completely lacking in approximately 0.5% of patients.
Here we describe the clinical and genetic background and
summarize recommendations for the genetic testing and
tailoring of treatment with 5-FU derivatives. The statement
was developed as a consensus statement organized by the
German Society for Hematology and Medical Oncology in
cooperation with 13 medical associations from Austria, Germany, and Switzerland. Key Messages: (i) Patients should be
tested for the 4 most common genetic DPYD variants before
treatment with drugs containing FU. (ii) Testing forms the
basis for a differentiated, risk-adapted algorithm with recommendations for treatment with FU-containing drugs. (iii)
Testing may optionally be supplemented by therapeutic
drug monitoring
Synthesis of a Tetradehydro-Disorazole C1 Niess, Barbara; Hartung, Ingo V.; Haustedt, Lars O. ...
European Journal of Organic Chemistry,
March 2006, Volume:
2006, Issue:
5
Book Review
